Addiction of melanoma cells to the MAPK cascade-related oncogene activity is therapeutically targeted by selective inhibitors of mutated B-RAF proto-oncogene (BRAFmut) and mitogen-activated protein kinase 1/2 (MEK1/2) that have produced a robust response of melanoma patients [2,3,4]. Here, BRAF is linked to melanoma.